Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles A Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that non-germinal center B-cell-like (non-GCB) patients have significantly worse outcome with this regimen. We evaluated the prognostic significance of baseline risk factors, including cell of origin (COO) classified by the Hans algorithm, within an alternative chemoimmunotherapy program. At Memorial Sloan Kettering Cancer Center (MSK), 151 patients with DLBCL received sequential R-CHOP induction and (R)-ICE (rituximab, ifosfamide, carboplatin, and etoposide) consolidation...
January 25, 2024: Blood Advances